Elesta EchoLaser results of the first USA clinical trial presented at AUA 2022 in New Orleans.
Click the link below to read about the new results presented in AUA22 congress! https://markets.businessinsider.com/news/stocks/ultrasound-and-elesta-announces-first-clinical-data-for-echolaser-for-tpla-presented-at-aua-2022-1031488936
SoracteLite & Aramed
Aramed porta nel mondo la nostra tecnologia SoracteLite
Korian Group: Echolaser, laser-ultrasound technology for prostate and thyroid treatment
Ruetir February 22, 2022 The innovative micro-invasive EchoLaser system will allow the facilities of the Korian group to provide an even excellent service to their patients suffering from prostate and thyroid pathologies. The scope is to reduce the time of the...
Delphi Consensus – EchoLaser SoracteLite
January 14, 2022 Consequent to the rapid increase of the hospitals where EchoLaser SoracteLite is used to treat BPH, Elesta has initiated a national project for the elaboration of a Delphi Consensus (which will be submitted for publication), aiming at standardizing...
New CPT Code Has Been Approved by the AMA for Transperineal Laser Ablation of the Prostate
November 1, 2021 Effective from July 1, 2022, the specific CPT code will allow EchoLaser SoracteLite treatment to spread quickly, with benefits for hospitals, payers and most of all patients. Click here to get more details.